AR103840A1 - ANTICUERPOS IgG MODIFICADOS QUE SE UNEN AL FACTOR DE CRECIMIENTO TRANSFORMANTE b1 CON AFINIDAD, AVIDEZ Y ESPECIFICIDAD ELEVADAS - Google Patents
ANTICUERPOS IgG MODIFICADOS QUE SE UNEN AL FACTOR DE CRECIMIENTO TRANSFORMANTE b1 CON AFINIDAD, AVIDEZ Y ESPECIFICIDAD ELEVADASInfo
- Publication number
- AR103840A1 AR103840A1 ARP160100560A ARP160100560A AR103840A1 AR 103840 A1 AR103840 A1 AR 103840A1 AR P160100560 A ARP160100560 A AR P160100560A AR P160100560 A ARP160100560 A AR P160100560A AR 103840 A1 AR103840 A1 AR 103840A1
- Authority
- AR
- Argentina
- Prior art keywords
- modified igg
- high affinity
- specificity
- bind
- advance
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562128149P | 2015-03-04 | 2015-03-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR103840A1 true AR103840A1 (es) | 2017-06-07 |
Family
ID=55524479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160100560A AR103840A1 (es) | 2015-03-04 | 2016-03-03 | ANTICUERPOS IgG MODIFICADOS QUE SE UNEN AL FACTOR DE CRECIMIENTO TRANSFORMANTE b1 CON AFINIDAD, AVIDEZ Y ESPECIFICIDAD ELEVADAS |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US11325970B2 (https=) |
| EP (3) | EP4495137A3 (https=) |
| JP (1) | JP6745275B2 (https=) |
| KR (3) | KR102560072B1 (https=) |
| CN (1) | CN107787329B (https=) |
| AR (1) | AR103840A1 (https=) |
| AU (1) | AU2016226098B2 (https=) |
| DK (1) | DK3265487T3 (https=) |
| ES (2) | ES2927297T3 (https=) |
| HR (1) | HRP20221142T1 (https=) |
| HU (1) | HUE059644T2 (https=) |
| IL (1) | IL254239B2 (https=) |
| LT (1) | LT3265487T (https=) |
| MX (1) | MX382703B (https=) |
| PL (1) | PL3265487T3 (https=) |
| PT (1) | PT3265487T (https=) |
| RS (1) | RS63589B1 (https=) |
| RU (1) | RU2728858C2 (https=) |
| SG (2) | SG10201908019UA (https=) |
| SI (1) | SI3265487T1 (https=) |
| TW (1) | TWI733661B (https=) |
| WO (1) | WO2016141245A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI733661B (zh) | 2015-03-04 | 2021-07-21 | 美商健臻公司 | 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體 |
| TWI726870B (zh) | 2015-03-04 | 2021-05-11 | 美商健臻公司 | 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體 |
| CA3055555A1 (en) | 2016-03-11 | 2017-09-14 | Scholar Rock, Inc. | Tgf.beta.1-binding immunoglobulins and use thereof |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| TWI787230B (zh) | 2017-01-20 | 2022-12-21 | 法商賽諾菲公司 | 抗ＴＧＦ-β抗體及其用途 |
| TWI832600B (zh) | 2017-01-20 | 2024-02-11 | 美商健臻公司 | 骨靶向抗體 |
| AU2019266042B2 (en) * | 2018-05-10 | 2025-08-07 | Mirabiologics Inc. | Artificial protein containing an antibody antigen-binding region, fused with bioactive peptides |
| MA53125A (fr) | 2018-07-11 | 2021-05-19 | Scholar Rock Inc | Inhibiteurs de tgf?1 sélectifs selon l'isoforme à affinité élevée |
| US20220119513A1 (en) * | 2020-06-08 | 2022-04-21 | Zoetis Services Llc | Anti-tgfb antibodies and therapeutic uses thereof |
| MX2022015304A (es) * | 2020-06-12 | 2023-03-23 | Bristol Myers Squibb Tgf Beta Inc | Agentes de union al factor de crecimiento transformante beta (tgfbeta) y usos de los mismos. |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020099179A1 (en) | 1989-12-21 | 2002-07-25 | Linda K. Jolliffe | Cdr-grafted antibodies |
| US5616561A (en) | 1995-03-31 | 1997-04-01 | Regents Of The University Of California | TGF-β antagonists as mitigators of radiation-induced tissue damage |
| US6492497B1 (en) * | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
| EP1486560A3 (en) | 1999-04-30 | 2005-02-09 | Cambridge Antibody Technology LTD | Specific antibodies and antibody fragments for TGFBETA1 |
| JP2006525362A (ja) | 2003-04-30 | 2006-11-09 | ジェンザイム コーポレーション | 腎機能不全を治療するためのＴＧＦ−βアンタゴニストとレニン−アンジオテンシン−アルドステロン系アンタゴニストとの併用 |
| EP1740615B1 (en) * | 2004-03-31 | 2014-11-05 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| CN101084007A (zh) * | 2004-09-22 | 2007-12-05 | 金齐姆公司 | TGF－β拮抗剂限制免疫抑制剂肾毒性的用途 |
| US9284375B2 (en) | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| BRPI0608376A8 (pt) | 2005-04-22 | 2018-10-16 | Lilly Co Eli | composição de ligação, método de uso de uma composição de ligação, e, kit de detecção |
| EP1966243B1 (en) | 2005-12-23 | 2012-02-15 | Eli Lilly And Company | Tgf-beta binding antibodies |
| CA2646508A1 (en) | 2006-03-17 | 2007-09-27 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
| JP4294082B2 (ja) | 2006-03-23 | 2009-07-08 | 協和発酵キリン株式会社 | ヒトトロンボポエチン受容体に対するアゴニスト抗体 |
| MX2009003518A (es) * | 2006-10-03 | 2009-08-25 | Genzyme Corp | Uso de antagonistas de tgf-beta para tratar a los infantes en riesgo de desarrollar displasia brocopulmonar. |
| MX2011000071A (es) | 2008-07-02 | 2011-05-03 | Emergent Product Dev Seattle | Inmunoterapeuticos de interleucina-6 (il6). |
| WO2010124276A2 (en) * | 2009-04-24 | 2010-10-28 | Vanderbilt Universtiy | Anti-tgf-beta induction of bone cell function and bone growth |
| EP2655624B1 (en) | 2010-12-23 | 2017-11-29 | Biogen MA Inc. | Linker peptides and polypeptides comprising same |
| TWI743461B (zh) | 2011-03-28 | 2021-10-21 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| CN103732623B (zh) | 2011-06-03 | 2017-09-29 | 佐马技术有限公司 | 对TGF‑β具有特异性的抗体 |
| IN2015DN01299A (https=) | 2012-07-23 | 2015-07-03 | Zymeworks Inc | |
| LT2971048T (lt) | 2013-03-11 | 2019-02-25 | Genzyme Corporation | Inžineriniu būdu gauti anti-tgf-beta antikūnai ir antigeną surišantys fragmentai |
| HRP20181939T4 (hr) * | 2013-03-20 | 2022-05-13 | Genzyme Corporation | Postupci za liječenje osteogenesis imperfecta |
| TWI726870B (zh) | 2015-03-04 | 2021-05-11 | 美商健臻公司 | 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體 |
| TWI733661B (zh) | 2015-03-04 | 2021-07-21 | 美商健臻公司 | 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體 |
-
2016
- 2016-03-02 TW TW105106247A patent/TWI733661B/zh active
- 2016-03-03 ES ES16709666T patent/ES2927297T3/es active Active
- 2016-03-03 RU RU2017134043A patent/RU2728858C2/ru active
- 2016-03-03 EP EP24203381.9A patent/EP4495137A3/en not_active Withdrawn
- 2016-03-03 KR KR1020177027372A patent/KR102560072B1/ko active Active
- 2016-03-03 WO PCT/US2016/020780 patent/WO2016141245A1/en not_active Ceased
- 2016-03-03 US US15/555,500 patent/US11325970B2/en active Active
- 2016-03-03 SI SI201631598T patent/SI3265487T1/sl unknown
- 2016-03-03 DK DK16709666.8T patent/DK3265487T3/da active
- 2016-03-03 KR KR1020247016764A patent/KR20240076851A/ko not_active Ceased
- 2016-03-03 CN CN201680025633.5A patent/CN107787329B/zh active Active
- 2016-03-03 EP EP16709666.8A patent/EP3265487B1/en active Active
- 2016-03-03 JP JP2017546179A patent/JP6745275B2/ja active Active
- 2016-03-03 HU HUE16709666A patent/HUE059644T2/hu unknown
- 2016-03-03 PT PT167096668T patent/PT3265487T/pt unknown
- 2016-03-03 SG SG10201908019U patent/SG10201908019UA/en unknown
- 2016-03-03 ES ES22180865T patent/ES2994790T3/es active Active
- 2016-03-03 AR ARP160100560A patent/AR103840A1/es unknown
- 2016-03-03 LT LTEPPCT/US2016/020780T patent/LT3265487T/lt unknown
- 2016-03-03 HR HRP20221142TT patent/HRP20221142T1/hr unknown
- 2016-03-03 EP EP22180865.2A patent/EP4163299B1/en active Active
- 2016-03-03 MX MX2017011252A patent/MX382703B/es unknown
- 2016-03-03 SG SG11201707109XA patent/SG11201707109XA/en unknown
- 2016-03-03 PL PL16709666.8T patent/PL3265487T3/pl unknown
- 2016-03-03 RS RS20220886A patent/RS63589B1/sr unknown
- 2016-03-03 KR KR1020237024971A patent/KR102668864B1/ko active Active
- 2016-03-03 AU AU2016226098A patent/AU2016226098B2/en active Active
-
2017
- 2017-08-31 IL IL254239A patent/IL254239B2/en unknown
-
2022
- 2022-04-11 US US17/717,967 patent/US11834495B2/en active Active
-
2023
- 2023-10-23 US US18/492,150 patent/US12162933B2/en active Active
-
2024
- 2024-11-06 US US18/939,307 patent/US20250179163A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR103840A1 (es) | ANTICUERPOS IgG MODIFICADOS QUE SE UNEN AL FACTOR DE CRECIMIENTO TRANSFORMANTE b1 CON AFINIDAD, AVIDEZ Y ESPECIFICIDAD ELEVADAS | |
| CL2020002305A1 (es) | Uso de anticuerpos sirpa v1 antihumanos y procedimiento de producción de anticuerpos anti-sirpa v1 | |
| MX2022003718A (es) | Anticuerpos que se unen a cd39 y sus usos. | |
| JOP20190292A1 (ar) | استخدام الأجسام المضادة لربط il-1? في علاج السرطان | |
| PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
| CO2018000886A2 (es) | Anticuerpos biespecíficos para pd1 y tim3 | |
| PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion | |
| PE20151289A1 (es) | Anticuerpos que se unen al tl1a y sus usos | |
| CO2017005388A2 (es) | Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales | |
| UY36965A (es) | Proteínas de unión triespecíficas y/o trivalentes para la prevención o el tratamiento de la infección por vih | |
| AR101846A1 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
| MX2021001268A (es) | Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos. | |
| MX2020013631A (es) | Variantes de anticuerpo grupo de diferenciacion (cd38) y usos de las mismas. | |
| ECSP20014362A (es) | Anticuerpos multiespecíficos que se unen específicamente a los epítopos del virus del zika y usos de los mismos | |
| EA201690803A1 (ru) | Получение переориентирующих т-клетки гетеродимерных иммуноглобулинов | |
| PE20161032A1 (es) | Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion | |
| CO2019005101A2 (es) | Anticuerpo biespecífico heterodimérico estructural de anticuerpo natural anti-pd-1/anti-her2 y método para preparar el mismo | |
| PE20200927A1 (es) | Anticuerpos monoclonales que se unen a la region de la cadena beta de la familia trbv9 del receptor de las celulas t humanas | |
| CL2019002894A1 (es) | Anticuerpo monoclonal para pd-l1. | |
| MX2022009915A (es) | Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos. | |
| PE20170943A1 (es) | Anticuerpos que se unen a ccr6 y sus usos | |
| AR109683A1 (es) | Anticuerpos contra el factor xi y sus usos | |
| EA201992460A1 (ru) | Антитела-агонисты btla и их применение | |
| EA201891594A1 (ru) | Антитела к il-17c | |
| MX375897B (es) | Novedoso anticuerpo anti-presepsina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |